MedTrace Logo

Cetuximab Monotherapy Maintenance Treatment in mCRC

NCT02978313 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2016-11-30

No results posted yet for this study

Summary

Investigating the efficacy of Cetuximab Monotherapy versus Continuation after induction treatment with chemotherapy + Cetuximab in inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks with mFOLFOX6/FOLFIRI and Cetuximab treatment. Reinduction treatment will be done in case of progression.

Conditions

Interventions

DRUG

Cetuximab

anti-EGFR monoclonal antibody

DRUG

mFOLFOX6

Oxaliplatin+LV5FU2

DRUG

FOLFIRI

Irinotecan+LV5FU2

Sponsors & Collaborators

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Yifeng Wang, MD · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-11-30
Completion
2019-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978313 on ClinicalTrials.gov